← Back to Patent Explorer
US6284284B1 Expired / Lapsed US ⏱️ 0.0 years remaining

Compositions and methods for production and use of an injectable naturally secreted extracellular matrix

Assignee: Organogenesis Inc
•
Filing: 1998-10-29
•
Granted: 2001-09-04
•
Expires: 2018-10-29
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The present invention discloses compositions containing natural human extracellular matrices and methods for the use thereof. More particularly, the present invention provides compositions and methods for the repair of skin defects using natural human extracellular matrix by injection.

Inventors

  • 👤 Gail K. Naughton

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-29 01:50
CPC Classifications
A; A61; A61L; A61L27/00; A61L27/36; A61L27/3604; A61L27/3633; A61L27/3683; A61L27/38; A61L27/3804; A61L27/3839; A61L27/50; A61L27/60; A61Q; A61Q19/00; A61Q19/08; A61F; A61F2/00; A61F2/0059; A61F2/02; A61F2/10; A61F2/105; Y; Y10; Y10T; Y10T442/00; Y10T442/20; Y10T442/2525

Claims Analysis

Total Claims: 17
Claim 1
Independent Claim 55 words
A method for the repair of a skin defect comprising: injecting a human secreted extracellular matrix comprising a mixture of cell-free, naturally secreted human extracellular components derived from living stromal tissue formulated for in vivo administration by injection via a syringe and a pharmaceutically acceptable carrier at a site of a skin or tissue defect.
Claim 2
Independent Claim 55 words
A method for the repair of a skin defect comprising: injecting a human secreted extracellular matrix comprising a mixture of cell-free, naturally secreted human extracellular components derived from living stromal tissue formulated for in vivo administration by injection via a syringe and a pharmaceutically acceptable carrier at a site of a skin or tissue defect.
Claim 3
Dependent Claim 138 words
The method according to claim 1 in which the naturally secreted extracellular matrix is produced by a method comprising: (a) providing a living stromal tissue prepared in vitro comprising human stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework, said framework composed of a biocompatible, non-living material formed into a three-dimensional structure having interstitial spaces bridged by the stromal cells; (b) killing the cells in the living stromal tissue; (c) removing the killed cells and any cellular contents from the framework; (d) collecting the connective tissue proteins naturally secreted by the stromal cells attached to the framework; and (e) processing the collected connective tissue proteins of step (d) with a pharmaceutically acceptable carrier into a formulation that is suitable for in vivo administration by injection via a syringe.
Claim 4
Dependent Claim 37 words
The method according to claim 2 in which the collected connective tissue proteins of step (d) are processed by homogenizing, cross-linking, or suspending the collected connective tissue proteins in a physiological acceptable carrier prior to step (e).
Claim 5
Dependent Claim 33 words
The method according to claim 2 in which the collected connective tissue proteins of step (d) are processed by adjusting ratios of collagen types I-V, respective to each other, prior to step (e).
Claim 6
Dependent Claim 18 words
The method according to claim 2 in which the stromal cells of the living stromal tissue are fibroblasts.
Claim 7
Dependent Claim 26 words
The method according to claim 2 in which the stromal cells of the living stromal tissue are cells found in loose connective tissue or bone marrow.
Claim 8
Dependent Claim 30 words
The method according to claim 6 in which the stromal cells of the living stromal tissue are endothelial cells, pericytes, macrophages, monocytes, leukocytes, plasma cells, mast cells, chondrocytes or adipocytes.
Claim 9
Dependent Claim 16 words
The method according to claim 2 in which the framework is composed of a biodegradable material.
Claim 10
Dependent Claim 22 words
The method according to claim 8 in which the biodegradable material is cotton, polyglycolic acid, cat gut sutures, cellulose, gelatin, or dextran.
Claim 11
Dependent Claim 16 words
The method according to claim 2 in which the framework is composed of a non-biodegradable material.
Claim 12
Dependent Claim 32 words
The method according to claim 10 in which the non-biodegradable material is a polyamide, a polyester, a polystyrene, a polypropylene, a polyacrylate, a polyvinyl, a polycarbonate, a polytetrafluoroethylene, or a nitrocellulose compound.
Claim 13
Dependent Claim 31 words
The method according to claim 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 or 11 in which the framework is a mesh.
Claim 14
Dependent Claim 21 words
The method according to claim 12 in which the framework has pore spaces of about 150 μm to about 220 μm.
Claim 15
Dependent Claim 26 words
The method according to claim 2 in which the pharmaceutically acceptable carrier contains an anesthetic agent, a lubricating agent, a tissue growth factor or combinations thereof.
Claim 16
Dependent Claim 131 words
The method according to claim 1 in which the naturally secreted extracellular matrix is produced by a method comprising: (a) providing a living stromal tissue prepared in vitro comprising human stromal cells and connective tissue proteins naturally secreted by the stromal cells attached to and substantially enveloping a framework, said framework composed of a biocompatible, non-living biodegradable material formed into a three-dimensional structure having interstitial spaces bridged by the stromal cells; (b) killing the cells in the living stromal tissue; (c) removing the killed cells and any cellular contents from the framework; and (d) processing the connective tissue proteins naturally secreted by the stromal cells attached to the framework and the biodegradable framework with a pharmaceutically acceptable carrier into a formulation suitable for in vivo administration by injection via a syringe.
Claim 17
Dependent Claim 38 words
The method according to claim 6 in which the stromal cells of the living stromal tissue are glial cells, liver cells, hematopoietic cells, dermal cells, lens fiber cells, smooth muscle cells, osteoblast cells, odontoblast cells, or retinal cells.

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 2004-09-03 2005-03-05 2005-09-04 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 2008-09-03 2009-03-05 2009-09-04 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2012-09-03 2013-03-05 2013-09-04 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag